Global IgA Nephropathy Treatment Patterns from a 2021 Real-World Survey

A 2021 survey of 174 nephrologists and 869 patients across eight countries provides data on real-world treatment patterns for immunoglobulin A nephropathy (IgAN). The dataset includes patient demographics, clinical characteristics, treatment lines, and unmet needs, with results reported using descriptive statistics. The supplementary material was authored by a figshare admin for Karger and is licensed under CC-BY-4.0.

Use Cases

• Analyzing regional variations in first-line treatment prescriptions based on the described global survey.
• Modeling the relationship between proteinuria levels and treatment lines as reported in the survey results.
• Studying the time from diagnosis to treatment initiation using the reported median and range values.
• Benchmarking real-world use of renin–angiotensin system inhibitors (RASi) and corticosteroids against clinical guidelines.

Strengths

• Includes data from 869 patients and 174 nephrologists across eight major countries, providing a multi-regional perspective.
• Reports specific clinical metrics, such as a mean patient age of 41.6 years and median proteinuria of 1.8 g/day at diagnosis.
• Details treatment patterns across multiple lines, including the percentage of patients receiving RASi and corticosteroids.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale modeling.
• Data may reflect geographic and temporal bias inherent to a 2021 survey-based study.

Provenance

Source

figshare admin karger

Collection Method

Retrospective analysis of a cross-sectional, survey-based study completed by nephrologists and patients.

Time Range

2021

Freshness

Last updated 2026-05-22 05:55:14; freshness should be verified.

Geography

United States, China, Japan, France, Germany, Italy, Spain, United Kingdom